StockData

Bausch Health Companies vs Viatris

BHC and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BHC and VTRS compare

Viatris is the larger company, worth 7.4 times as much as Bausch Health Companies ($23.5B against $3.2B).

Bausch Health Companies grew revenue faster over the last twelve months (10.8% versus 4.4% for Viatris).

Viatris pays a dividend yielding 2.3%; Bausch Health Companies does not pay one.

Bausch Health Companies scores higher on the StockData Score (8 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBHCVTRS
Size and price
Market cap$3.2B$23.5B
Share price$8.47$20.45
Change, 1 year34.9%90.8%
Change, 5 years−66.5%60.4%
Beta (5Y)0.900.34
Employees20K30K
StockData Score
Total score8 (better)6
Valuation score4 (better)2
Growth score2 (better)1
Performance score1 (better)0
Health score11
Dividend score02 (better)
Valuation
P/S0.3× (better)1.6×
EV/EBITDA9.3× (better)13.2×
P/FCF1.7× (better)12.0×
FCF yield58.8% (better)8.3%
Fair value$35.68$22.40
Margin of safety76.3% (better)8.7%
Growth
Revenue growth (TTM)10.8% (better)4.4%
Revenue growth, 5Y average5.0% (better)3.7%
Net income growth (TTM)−332%–
EPS growth (TTM)−336%–
Profitability
Gross margin–34.8%
Operating margin11.2% (better)−0.59%
Net margin−7.6%–
FCF margin16.8% (better)13.3%
Return on invested capital5.5%–
Financial health
Net debt / EBITDA7.574.59 (better)
Interest coverage0.8× (better)−0.2×
Current ratio1.561.58 (better)
Altman Z-score0.231.20 (better)
Piotroski F-score6–
Dividends and buybacks
Dividend yield–2.3%
Years of dividend growth–0
Buyback yield–1.3%
Shareholder yield0.00%3.6% (better)
Ownership
Held by institutions63.4%91.5%
Held by insiders31.5%0.36%
Insider net buying, 12 months−$507K (better)−$1.1M
Superinvestors holding13 (better)
Short interest, % of float2.9%3.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.